New guidelines give a thumbs down for routine use of next generation sequencing (NGS) in common cancers such as breast cancer – but a thumbs up in other tumours types such as advanced non-squamous NSCLC, prostate cancer, ovarian cancer and cholangiocarcinoma. The European Society for Medical Oncology (ESMO) recommendations for the use of next generation ...
ESMO verdict on next generation sequencing
By Mardi Chapman
28 Aug 2020